Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 10, 2016

Primary Completion Date

October 28, 2020

Study Completion Date

April 24, 2023

Conditions
Colorectal Cancer
Interventions
DRUG

Oxaliplatin

"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"

DRUG

LV5FU or Folfiri

Association of chemotherapy by LV5FU or Folfiri according pratician choice

DRUG

Oxycodone

Oxycodone

Trial Locations (1)

34298

Institut réginal du Cancer de Montpellier, Montpellier

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT03253133 - Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC | Biotech Hunter | Biotech Hunter